Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are getting pummeled in response to bad news for the company's experimental cystic fibrosis therapy. Investors unhappy about a paused clinical trial have beaten shares of the clinical-stage biopharmaceutical company 27.9% lower as of 11:46 a.m. EDT on Friday.
Today, Arrowhead Pharmaceuticals told investors it was voluntarily pausing an early-stage safety study of ARO-ENaC and healthy volunteers. Signals of lung inflammation among rats in a separate chronic toxicology study were the reason for the pause.
Image source: Getty Images.
Source Fool.com
